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with carotid artery stenosis and reduced 
under metformin treatment
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Abstract 
Background: Neutrophil gelatinase‑associated lipocalin (NGAL), an acute phase protein released by neutrophils, has 
been described as biomarker of inflammatory states. Type 2 diabetes mellitus (T2DM) is characterized by increased 
inflammation and an elevated risk for embolization of carotid artery stenosis (CAS). We aimed to explore the role of 
NGAL systemically and in plaques of diabetics undergoing carotid endarterectomy. Moreover, the potential anti‑
inflammatory effect of metformin on NGAL was addressed in diabetics.
Methods: Serum NGAL and matrix metalloproteinase (MMP)‑9/NGAL levels were measured in 136 patients (67 with 
T2DM vs. 69 non‑diabetics) by specific ELISA. Endarterectomy samples were graded histologically according to the 
American Heart Association´s classification. NGAL mRNA expression was detected using RealTime‑PCR in carotid 
endarterectomy specimens.
Results: Serum NGAL [median 107.4 ng/ml (quartiles: 75.2–145.0) vs. 64.4 (50.4 –81.3), p < 0.0001] and MMP‑9/NGAL 
[41.5 ng/ml (20.8–63.9) vs. 27.6 (16.0–42.4), p = 0.017] were significantly elevated in diabetics compared to non‑dia‑
betics, as were leukocytes, neutrophils, C‑reactive protein and fibrinogen (all p < 0.05). In patients with symptomatic 
and asymptomatic CAS diabetics had higher NGAL levels compared to non‑diabetics [128.8 ng/ml (100.8–195.6) vs. 
64.8 (48.9–82.2] and [101.6 ng/ml (70.1–125.3) vs. 63.8 (51.0–81.3), respectively, both p < 0.0001]. Presence of T2DM 
and type VI plaques (with surface defect, hemorrhage or thrombus) had a profound impact on NGAL levels (both 
p < 0.01) in multiple linear regression analysis. NGAL mRNA was detectable in 95% of analyzed carotid artery lesions of 
diabetics compared to 5% of non‑diabetics (p < 0.0001). Accordingly, cerebral embolization was more frequent in dia‑
betics (52.2% vs. 29%, p = 0.006). Metformin treatment was associated with decreased NGAL [60.7 ng/ml (51.9–69.2) 
vs. 121.7 (103.7–169.9), p < 0.0001] and MMP‑9/NGAL [20.8 ng/ml (12.1–26.5) vs. 53.7 (27.4–73.4), p = 0.007] in diabet‑
ics and reduced leukocyte infiltration in carotid lesions of diabetics.
Conclusions: Higher NGAL levels in serum and plaques are associated with T2DM in patients with CAS. Metformin 
significantly reduced the inflammatory burden including NGAL in diabetics. Early treatment of these patients may be 
recommended, as elevated NGAL levels were linked with vulnerable plaques prone for embolization.
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Introduction
Type II diabetes mellitus (T2DM) is one of the larg-
est epidemics in the world. In 2015 about 420 million 
people were suffering from T2DM worldwide, and it 
has been estimated that the number will increase to 
more than 640 million by 2040 [1]. Since the introduc-
tion of the “Framingham study” in 1979 the increased 
risk for cardiovascular events in patients with T2DM is 
well known [2]. Their incidence for ischemic strokes, of 
which about 30% are related to carotid artery stenosis 
(CAS), is 2.5–3.5 times higher compared to non-diabetics 
[3, 4]. Although good glycemic control is able to reduce 
the risk for cardiac events, the risk for ischemic stroke 
remains unaltered [4]. Consequently, this may cause per-
sistent functional impairment or even death in numerous 
patients.
Multiple pathophysiological pathways have been made 
responsible for the development of atherosclerosis pro-
moting vascular inflammation and thrombosis [5–12]. 
Patients with T2DM are especially prone to inflamma-
tory processes, which lead among others to endothe-
lial dysfunction [7, 13, 14]. Pro-inflammatory cytokines 
[such as interleukins (IL-1, IL-6), and tumour necrosis 
factor (TNF)-α] as well as chemokines and adhesion 
molecules have been shown to contribute to vascular 
complications in T2DM [13, 15]. The enhanced inflam-
matory state in type 2 diabetics was also documented by 
increased macrophage invasion in carotid plaques and 
elevated matrix metalloproteinase (MMP)-9 levels [16–
19]. MMP-9 plays a crucial role in plaque instability as it 
is able to degrade the extracellular matrix and in particu-
lar collagen [20, 21].
Neutrophil gelatinase-associated lipocalin (NGAL) 
or lipocalin 2, which is mainly released from granules 
of activated neutrophils, was recognized as an acute 
phase protein [22]. Increased NGAL levels have been 
reported in atherosclerosis and linked to inflammatory 
processes [23–30]. NGAL is able to bind to MMP-9 and 
to form a dimeric MMP-9/NGAL complex, which pro-
longs the deleterious effects of MMP-9 on the arterial 
wall, as MMP-9 degradation is thereby prevented [31]. 
Previous works have shown that NGAL is expressed by 
macrophages, smooth muscle cells and endothelial cells 
in human carotid plaques [23, 25]. In addition, we dem-
onstrated that NGAL up-regulated the production of 
pro-inflammatory cytokines IL-6, IL-8, and monocyte 
chemoattractant protein (MCP)-1 in these cells in  vitro 
[23]. Moreover, NGAL may serve as potential circulating 
biomarker of plaque vulnerability in patients with CAS, 
as was shown by our group recently [24].
The aim of our present study was to investigate, 
whether serum NGAL and MMP-9/NGAL levels were 
elevated in type 2 diabetics with CAS in comparison to 
non-diabetics, and whether NGAL levels could reflect 
the inflammatory state, defined clinically and histologi-
cally, of these patients. Furthermore, we wanted to know 
if neurological events correlated to NGAL levels. Moreo-
ver, NGAL mRNA expression in carotid plaques of dia-
betics vs. non-diabetics was analyzed. In addition, we 
looked at NGAL levels under treatment of metformin in 
diabetic patients with CAS.
Materials and methods
Patient’s selection
One hundred and thirty-six patients with high grade 
CAS treated with endarterectomies at the Medical Uni-
versity of Vienna, Austria, were included in the study. 
Patients with acute or chronic infections, autoimmune or 
neoplastic diseases were excluded. All subjects were Cau-
casian. The study has been reviewed and approved by the 
Ethic Committee of the Medical University of Vienna (EK 
269/2009), and all participants gave informed consent.
The patients’ cohort comprised 67 patients with T2DM 
and 69 non-diabetics. The diagnosis of T2DM was based 
on the criteria established by the American Diabetes 
Association in 2010 and the WHO criteria of 2011 [32]. 
Patients with glycated hemoglobin  (HbA1c) >6.5%, fasting 
plasma glucose ≥7  mmol/l or 2  h postload plasma glu-
cose ≥11.1 mmol/l were regarded as type 2 diabetics [32, 
33]. Anti-diabetic treatment comprised metformin, insu-
lin or other anti-diabetic drugs.
Asymptomatic patients with high grade CAS and/or 
vulnerable, high-risk plaques according to ultrasound 
examination have been operated as well as sympto-
matic patients having had at least one neurological event 
directly associated with CAS within the last 6  months 
[34]. Coronary artery disease (CAD) and arterial hyper-
tension was defined according to the American Heart 
Association (AHA) [35]. Preoperative duplex sonogra-
phy was used to classify carotid plaques according to 
echogenicity into “soft”, calcified/hard and mixed lesions. 
Furthermore, extent of CAS (in percentage) and blood 
velocity (in m/sec) was recorded.
Carotid endarterectomy
Carotid endarterectomy was performed under general 
anesthesia via the “non-touch” technique. Protective 
hypertension was used or shunting if oxygen saturation 
decreased intraoperatively by more than one-third. Sys-
temic heparinisation (unfractionated, adjusted to body 
weight and renal function) was administered at the 
beginning of the operation to prevent from embolization. 
Endarterectomy was performed via a linear arteriotomy 
and the plaque removed for histological and biochemical 
evaluation. Distal intimal tacking sutures were applied 
when necessary and routine patching was performed.
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Blood sampling
Blood was taken from a peripheral vein prior to surgery. 
All blood samples were centrifuged at 3000 rpm at 4  °C 
for 15 min and serum and plasma were stored in aliquots 
at −80 °C for further analysis.
NGAL and MMP‑9/NGAL measurement
Neutrophil gelatinase-associated lipocalin and MMP-9/
NGAL levels were measured by specific enzyme-linked 
immunosorbent assays (ELISA, both from R&D Systems; 
catalog number DLCN20 and DM9L20, respectively) in 
serum of 136 patients. Investigators blinded to clinical 
and demographic data performed assays.
Total RNA purification and cDNA preparation
Atherosclerotic tissue (i.e. endarterectomized plaques) 
from 39 patients was available for total RNA purification 
and stored at −80 °C. Frozen samples were homogenized 
using a ball mill (Retsch, Haan, Germany), and mRNA 
were isolated using  RNeasy® Mini Kit (Quiagen, Valen-
cia, CA, USA). Total RNA content was measured using 
NanoDrop (Thermo Scientific, Barrington, IL, USA). 
Reverse transcription were performed using GoScript™ 
reverse transcription system (Promega, Madison, WI, 
USA).
Real‑time polymerase chain reaction
Real-time-PCR was performed using LightCycler Taq-
Man Master (Roche, Basel, Switzerland) according to the 
manufacturer’s instructions. Primers (forward (fwd) and 
reverse (rev)) were designed using the Roche Universal 
ProbeLibrary Assay Design Centre (http://www.universal-
probelibrary.com/): glycerinaldehyd-3-phosphat-dehydro-
genase (GAPDH) (fwd: AGCCACATCGCTCAGACAC, 
rev: GCCCAATACGACCAAATCC, UPLprobe #60; 
Amplicon Size [bp] 66)—NGAL (fwd: CAGGACTCCAC 
CTCAGACCT; rev: CCAGGCCTACCACATACCAC, 
UPLprobe #84; Amplicon Size [bp] 109). The amplifica-
tion conditions consisted of an initial incubation at 95 °C 
for 10 min, followed by 45 cycles of 95 °C for 10 s, 63 °C 
for 20 s and 72 °C for 6 s and a final cooling to 40 °C. Data 
were analyzed using Light-Cycler Software Version 3.5 
(Roche).
Histology
Histological classification of endarterectomy specimens 
was performed according to the AHA [36]. Plaques 
were assorted into type IV plaques (confluent extracel-
lular lipid core), type V (fibroatheroma), type VI (com-
plex plaque with possible surface defect, hemorrhage, 
or thrombus), type VII (calcified plaques), and type VIII 
plaque (dominated fibrous tissue). Paraffin-embedded 
specimen were cut in 4  µm thick sections and stained 
with hematoxylin and eosins (H&E), Elastica van Gieson 
and alcian blue. The analyzing pathologist was blinded 
to clinical and demographic data. Descriptive analysis of 
histological specimen was added with special reference 
to leukocyte infiltration.
Statistical analysis
Median (quartile) values were given to describe continu-
ous variables; absolute numbers and percentages are used 
to describe categorical variables. Differences between 
patient groups with respect to NGAL and MMP-9/
NGAL levels, respectively, were tested by the two-sample 
t test. In case of more than two groups, analysis of vari-
ance models were performed, and the Tukey method was 
applied to correct for multiple comparisons. Differences 
in continuous variables of diabetes patients compared to 
non-diabetes patients were tested using the two-sample 
t test, non-normally distributed variables were compared 
by the Wilcoxon rank sum test. Categorical variables 
were compared by the Chi square test. Correlations of 
continuous variables were characterized using the Spear-
man correlation coefficient.
Univariate and multiple linear regression models were 
performed to evaluate the unadjusted and adjusted 
impact of the variables T2DM, creatinine, neutrophils, 
body mass index (BMI), plaque ultrasound, histological 
classification of the plaques and symptomatic presen-
tation of CAS on the NGAL and MMP-9/NGAL levels. 
Log-transformed values of neutrophils and MMP-9/
NGAL and rank-transformed values of creatinine were 
used for statistical analyses due to their skewed distribu-
tions. To evaluate the influence of anti-diabetic treatment 
on NGAL and MMP-9/NGAL levels in peripheral blood, 
diabetic patients were compared with respect to the three 
types of treatment: insulin, metformin, and other anti-
diabetic treatment. Furthermore, univariate and multiple 
linear regression models were applied on data of diabetic 
patients to evaluate the unadjusted impact of the treat-
ments on NGAL and MMP-9/NGAL and adjusted for 
HbA1c and neutrophils. All p values are results of two-
sided tests and p values <0.05 were considered as indicat-
ing statistical significance. The SAS software version 9.4 
(SAS Institute Inc. 2002–2012; Cary, NC, USA) was used 
for statistical analyses.
Results
Characteristics of study population
Detailed information of the study population is given 
in Table  1. Diabetic and non-diabetic patients were 
comparable in sex, age and BMI. Cardiovascular risk 
factors such as smoking and hypertension were also 
equally distributed in both groups. In contrast, diabet-
ics had an increased prevalence of CAD (39.4% vs. 22.1%, 
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p  =  0.030) and cerebral infarctions (52.2% vs. 29.0%, 
p = 0.006). Some of them exhibited silent infarctions. As 
a consequence 44.8% of diabetics were assessed as “symp-
tomatic” patients having experienced transient ischemic 
attacks (TIA) and strokes within the last 6  months vs. 
33.3% in non-diabetics (p = 0.171).
Statins (89.9% vs. 68.7%, p  =  0.002) and acetyl sali-
cylic acid (85.5% vs. 71.6%, p  =  0.048) were taken in a 
higher percentage in non-diabetic vs. diabetic patients. 
The prevalence of hyperlipidemia was higher in diabet-
ics (77.6% vs. 43.5%, p < 0.0001). In contrast, high-density 
lipoproteins (HDL) (52 mg/dl vs. 45 mg/dl, p = 0.01) and 
total cholesterol (170.5 mg/dl vs. 159 mg/dl, p =  0.037) 
were increased in non-diabetic patients. Low-density 
lipoproteins (LDL) and triglycerides showed no relevant 
difference in both patients groups (Table 1).
Inflammatory markers such as high sensitive-C-reactive 
protein (hs-CRP) (p  =  0.014), neutrophils (p  =  0.002), 
leukocytes (p =  0.03), and fibrinogen (p =  0.003) were 
significantly elevated in peripheral blood in diabetic 
vs. non-diabetic patients. Likewise,  HbA1c was higher 
in diabetics compared to non-diabetics (6.8% vs. 5.8%, 
p < 0.0001, Table 1).
NGAL and MMP‑9/NGAL serum levels
Neutrophil gelatinase associated lipocalin was signifi-
cantly higher in diabetic patients compared to non-
diabetics [107.4  ng/ml (75.2–145.0) vs. 64.4  ng/ml 
(50.4–81.3), p  <  0.0001, Fig.  1a]. The same was true for 
the MMP-9/NGAL complex [41.5  ng/ml (20.8–63.9) vs. 
27.6 ng/ml (16.0–42.4), p = 0.017, Fig. 1b].
Type 2 diabetics with symptomatic CAS had signifi-
cantly higher NGAL levels compared to symptomatic 
non-diabetics [128.8  ng/ml (100.8–195.6) vs. 64.8  ng/
ml (48.9–82.2), p < 0.0001, Fig. 2a]. Likewise, NGAL lev-
els were significantly elevated in asymptomatic patients 
with T2DM compared to asymptomatic non-diabetics 
[101.6  ng/ml (70.1–125.3) vs. 63.8  ng/ml (51.0–81.3), 
p < 0.0001, Fig. 2b]. MMP-9/NGAL levels, however, did 
not reach statistical significance when comparing symp-
tomatic diabetics [37.7  ng/ml (18.0–60.3)] vs. sympto-
matic non-diabetics [18.8  ng/ml (16.0–46.7), p =  0.11]. 
Table 1 Patient characteristics
Data are presented as frequencies or median (quartiles)
* t test
** Chi square test
++  Wilcoxon rank sum test
CAD coronary artery disease, TIA trans-ischaemic attack, T-ASS acetyl salicylic acid, ACE angiotensin-converting enzyme, LDL low-density lipoprotein, HDL high density 
lipoprotein, CRP C-reactive protein, HbA1c glycated hemoglobin
Diabetic patients (n = 67) Non‑diabetic patients (n = 69) p
Age (years), median (quartiles) 72.0 (64.0–75.0) 69.0 (64.0–74.0) 0.288*
Sex (female) (%) 40.3 49.3 0.293**
Body mass index (kg/m2), median (quartiles) 28.1 (24.7–30.5) 27.1 (24.2–29.1) 0.234*
Smoker (%) 39.4 36.8 0.754**
Hypertension (%) 85.1 87.0 0.752**+
Hyperlipidemia (%) 77.6 43.5 <0.0001**
CAD (%) 39.4 22.1 0.030**
Cerebral infarction (%) 52.2 29.0 0.006**
Symptomatic (TIA/Stroke) (%) 44.8 33.3 0.171**
T‑ASS (%) 71.6 85.5 0.048**
ACE‑inhibitor (%) 38.5 35.8 0.754**
Statins (%) 68.7 89.9 0.002**
Creatinine (mg/dl), median (quartiles) 0.98 (0.86–1.19) 0.88 (0.80–1.03) 0.023++
Total cholesterol (mg/dl), median (quartiles) 159.0 (132.5–188.5) 170.5 (151.5–205.5) 0.037++
LDL (mg/dl), median (quartiles) 83.5 (62.0–105.2) 83.6 (70.2–117.8) 0.351++
HDL (mg/dl), median (quartiles) 45.0 (37.0–55.0) 52.0 (43.0–63.0) 0.010*
Triglyceride (mg/dl), median (quartiles) 125.0 (95.5–211.5) 137.0 (95.5–179.0) 0.771++
Leukocytes (G/l), median (quartiles) 8.39 (7.10–10.03) 7.16 (6.38–9.02) 0.030*
Neutrophils (G/l), median (quartiles) 5.8 (4.7–6.8) 4.6 (3.9–6.1) 0.002++
CRP (mg/dl), median (quartiles) 0.68 (0.27–2.06) 0.43 (0.17–1.01) 0.014++
Fibrinogen (mg/dl), median (quartiles) 422.0 (382.0–490.0) 390.5 (330.5–438.5) 0.003++
HbA1c (%), median (quartiles) 6.8 (6.0–7.4) 5.8 (5.5–6.0) <0.0001*
Page 5 of 11Eilenberg et al. Cardiovasc Diabetol  (2017) 16:98 
Comparison of MMP-9/NGAL levels between asymp-
tomatic diabetics [45.8  ng/ml (23.2–63.9)] vs. asympto-
matic non-diabetics [31.7  ng/ml (17.8–42.4) p =  0.057] 
revealed a tendency towards higher MMP-9/NGAL lev-
els in diabetics.
HbA1c showed a positive correlation with NGAL levels 
(r =  0.38, p  <  0.001), but not with MMP-9/NGAL lev-
els (r  =  0.10, p  =  0.23). Positive correlations were also 
observed between NGAL and creatinine levels (r = 0.29, 
p = 0.0006) and neutrophil counts (r = 0.26, p = 0.003), 
respectively. The duration of T2DM did not correlate 
with NGAL (r = 0.03, p = 0.89) or MMP-9/NGAL levels 
(r = −0.16, p = 0.42). BMI did not show any correlation 
with NGAL (r = −0.01, p = 0.95) or MMP-9/NGAL lev-
els (r = 0.17, p = 0.05). Detailed results of Spearman cor-
relation analysis are listed in Table 2.
NGAL mRNA expression
Neutrophil gelatinase associated lipocalin mRNA expres-
sion was detected at a higher rate in atherosclerotic tis-
sue of patients with T2DM (in 19 of 20 patients, 95%) 
in comparison to non-diabetics (in 1 of 19 patients, 5%, 
p  <  0.0001). In addition, symptomatic CAS was found 
more frequently in type 2 diabetics with detectable 
Fig. 1 NGAL and MMP‑9/NGAL serum levels are higher in diabetics with CAS compared to non‑diabetics. Box‑whisker plot display serum NGAL (a) 
and MMP‑9/NGAL (b) concentrations stratified according to the presence of diabetes
Fig. 2 Association of NGAL with the symptomatic presentation of carotid artery stenosis. Box‑whisker plots display serum NGAL levels in patients 
with symptomatic (a) and asymptomatic carotid artery stenosis (b) stratified according to the presence of diabetes
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NGAL mRNA expression compared to non-diabetics 
[13/19 (68.4%) vs. 1/19 (5.3%), p  <  0.0001]. Diabetics 
with asymptomatic CAS showed a higher prevalence of 
detectable NGAL mRNA expression in carotid endar-
terectomy specimens compared to non-diabetics with 
asymptomatic CAS [6/6 (100%) vs. 0/0 (0%), p < 0.0001].
Histological findings
Vulnerable, grade VI plaques were found more frequently 
in patients with T2DM (n = 28/67, 41.79% vs. n = 11/69, 
15.94% in non-diabetics, p = 0.0009). Presence of stable, 
grade VII plaques did not differ significantly between 
both groups (n = 16/67, 23.88% in diabetics vs. n = 25/69, 
36.23% in non-diabetics, p = 0.12), nor did plaques grade 
V (fibroatheroma) (n  =  23/67, 34.33% in diabetics vs. 
n  =  33/69, 47.83% in non-diabetics, p  =  0.11). Histo-
logical classification according to the AHA revealed only 
one plaque grade VIII in the non-diabetes group and one 
plaque grade IV in each of both groups.
Univariate and multiple linear regression analysis
In the total cohort (both diabetic and non-diabetic 
patients), symptomatic CAS had an impact towards 
higher NGAL levels (p  =  0.0007) in univariate model. 
Moreover, histological class VI was associated with 
higher NGAL levels, whereas grade VII adversely affected 
NGAL (p < 0.0001). T2DM patients showed significantly 
higher NGAL levels (p  <  0.0001). Additionally, creati-
nine, neutrophils and plaques ultrasound gave statisti-
cally significant results in univariate models with respect 
to NGAL values. On contrary, BMI did not alter NGAL 
levels. Multiple linear regression analysis showed the fol-
lowing results: T2DM (p < 0.001), symptomatic presen-
tation (p = 0.023), histological classification (p < 0.0001) 
and plaque ultrasound (p  =  0.004) significantly influ-
ence NGAL levels. With respect to MMP9-NGAL lev-
els univariate regression analyses showed significant 
results for T2DM (p =  0.017), histological classification 
(p = 0.004), plaque ultrasound (p = 0.0004) and neutro-
phils (p < 0.0001). Multiple regression models only gave 
significant results for neutrophils (p = 0.010). Results of 
both univariate and multiple linear regression analysis 
are given in detail in Table 3A, B.
Metformin treatment
Diabetic patients with metformin therapy (n  =  17), 
regardless of additive treatment with insulin or other 
anti-diabetic treatment, showed significantly lower 
NGAL levels [60.7  ng/ml (51.9–69.2) vs. 121.7  ng/ml 
(103.7–169.9), p  <  0.0001, Fig.  3a] as well as MMP-9/
NGAL levels [20.8  ng/ml (12.1–26.5) vs. 53.7  ng/ml 
(27.4–73.4), p  =  0.007, Fig.  3b] compared to diabetics 
without metformin treatment. Insulin treatment alone 
(n = 16) had no effect on NGAL [88.7 ng/ml (59.0–118.6) 
vs. 111.6  ng/ml (78.6–145.9), p  =  0.14] and MMP-9/
NGAL levels [27.5  ng/ml (13.1–66.1) vs. 45.8  ng/ml 
(24.0–63.0), p  =  0.27] compared to diabetics without 
insulin treatment (n = 51). Likewise, other anti-diabetic 
medication (n  =  18) showed no influence on NGAL 
[101.2  ng/ml (76.3–126.6) vs. 110.6  ng/ml (72.9–145.9), 
p =  0.59] and MMP-9/NGAL levels [32.0  ng/ml (18.2–
59.1) vs. 44.7 ng/ml (24.0–65.9), p = 0.97] compared to 
diabetics with insulin and metformin. Within anti-dia-
betic treatment only metformin significantly influenced 
NGAL (p < 0.0001) and MMP-9/NGAL levels (p = 0.04) 
after adjustment in multiple linear regression analy-
ses model. Furthermore  HbA1c showed a statistically 
significant influence on NGAL (p  =  0.021) in multiple 
regression analysis on T2DM patients. Results of both 
univariate and multiple linear regression analysis are 
given in detail in Table 4A, B.
Histological analysis of carotid plaques showed mod-
erate signs of inflammation (i.e. infiltration of leuko-
cytes) in non-diabetics (Fig.  4a), whereas in patients 
with T2DM an infiltration with leukocytes was abundant 
(Fig. 4b). Finally, histologic analysis showed low signs of 
inflammation in type 2 diabetics with metformin intake 
(Fig. 4c) as compared to those without metformin intake 
(Fig.  4b). Moreover, vulnerable plaques types VI were 
extremely rare in patients with metformin treatment 
(n = 2/23, 8.7%).
Discussion
Inflammatory cells and cytokines trigger inflammatory 
cascades and play a fundamental role in the development 
and progression of atherosclerosis [5–12]. In patients suf-
fering from T2DM inflammatory processes are a cause 
of concern as hyperglycemia and insulin resistance as 
well as the underlying mechanisms contributing to vas-
cular complications may enhance development of plaque 
erosion, fissuring and rupture [13, 18, 19, 37]. To our 
Table 2 Correlation between  serum levels of  NGAL 
and  MMP-9/NGAL and  selected clinical and  laboratory 
parameters
r spearman correlation coefficient, HbA1c glycated hemoglobin, BMI body mass 
index
NGAL (ng/ml) MMP‑9/NGAL (ng/ml)
r p r p
HbA1c, % 0.38 <0.001 0.10 0.23
Creatinine, mg/dl 0.29 0.0006 −0.012 0.89
Neutrophil count, G/l 0.26 0.003 0.36 <0.0001
Duration T2DM, years 0.03 0.89 −0.16 0.42
BMI, kg/m2 −0.01 0.95 0.17 0.05
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knowledge, this is the first study that elucidates the asso-
ciation between NGAL in blood and carotid plaques and 
the underlying clinical and histological characteristics in 
type 2 diabetics with CAS undergoing carotid endarter-
ectomy as well as the influence of metformin treatment 
on NGAL levels in these patients.
Serum NGAL and MMP‑9/NGAL
In our study, serum NGAL and MMP-9/NGAL levels 
were significantly elevated, almost twice as high in diabet-
ics compared to non-diabetics. Moreover, multiple linear 
regression analysis showed a marked impact of T2DM on 
NGAL levels in our study. However, two previous reports 
showed contradictory results [38, 39]. Giaginis and cow-
orkers stated that plasma NGAL concentrations did not 
differ significantly in non-diabetics versus a small group 
of 33 diabetics with CAS [38]. First of all, the low num-
ber of patients may have contributed to these results. 
Furthermore, this study did not report anti-diabetic 
treatments. As our present data showed, diabetics under 
metformin treatment demonstrated significantly reduced 
serum NGAL and MMP-9/NGAL levels comparable with 
non-diabetics. Consequently, these factors may have pro-
foundly influenced the sub-group analysis by Giaginis 
et al. [38]. The second report, which failed to show differ-
ences of NGAL levels in patients with T2DM and CAS, 
was restricted to asymptomatic patients with early CAS. 
In addition, a relatively high number of young and female 
patients were included in that study [39]. Consequently, 
those patient cohorts are not comparable to that analyzed 
in the present study. Moreover, NGAL mRNA expression 
was detectable in 95% of patients with T2DM compared 
to 5% of non-diabetics in our study. This clearly indicates 
the increased expression of NGAL at cellular level in 
carotid atherosclerotic lesions in patients with T2DM.
Pro‑inflammatory markers
In our cohort, elevated well-established pro-inflamma-
tory markers and acute phase proteins such as hs-CRP, 
fibrinogen, and neutrophils, evidenced the inflamma-
tory burden of T2DM compared to non-diabetics. Ode-
gaard et al. [15] reported a positive association between 
Table 3 Univariate and multiple linear regression models for serum NGAL (A) and MMP-9/NGAL (B, log-transformed) con-
centrations in the total cohort
a Regression parameter (β) ± standard error (SE)
Univariate models Multiple model
β ± SEa p β ± SEa p
(A)
 BMI −0.21 ± 1.01 0.832 0.42 ± 0.67 0.532
 Creatinine (rank‑transformed) 0.32 ± 0.10 0.002 0.14 ± 0.07 0.056
 Neutrophils (log‑transformed) 35.9 ± 12.1 0.003 4.4 ± 8.6 0.609
 Plaque ultrasound <0.0001 0.004
 “calcified/hard”vs. “soft” −59.3 ± 7.3 −18.4 ± 7.6
 “mixed” vs. “soft” −55.5 ± 9.2 −26.1 ± 8.0
 Histological classification <0.0001 <0.0001
 Type VI vs. type V 56.6 ± 7.5 33.0 ± 7.3
 Type VII vs. type V −21.7 ± 7.4 −18.8 ± 6.8
 Symptomatic (yes vs. no) 27.8 ± 8.0 0.0007 12.9 ± 5.6 0.023
 T2DM (yes vs. no) 50.8 ± 6.9 <0.0001 29.1 ± 6.0 <0.0001
(B)
 BMI 0.03 ± 0.02 0.086 0.03 ± 0.02 0.100
 Creatinine (rank‑transformed) −0.001 ± 0.0020 0.517 −0.002 ± 0.002 0.391
 Neutrophils (log‑transformed) 0.89 ± 0.20 <0.0001 0.57 ± 0.22 0.010
 Plaque ultrasound 0.0004 0.257
 “calcified/hard”vs. “soft” −0.59 ± 0.15 −0.26 ± 0.19
 “mixed” vs. “soft” −0.49 ± 0.19 −0.31 ± 0.20
 Histological classification 0.004 0.196
 Type VI vs. type V 0.45 ± 0.17 0.27 ± 0.19
 Type VII vs. type V −0.13 ± 0.17 −0.12 ± 0.17
 Symptomatic (yes vs. no) −0.08 ± 0.15 0.602 −0.17 ± 0.14 0.239
 T2DM (yes vs. no) 0.34 ± 0.14 0.017 0.04 ± 0.15 0.801
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hs-CRP and T2DM in patients from the CARDIA study. 
Moreover, NGAL has been described as an inflamma-
tory marker, especially in metabolic complications [30, 
40]. Two other reports showed a positive correlation 
between hs-CRP and serum NGAL levels in patients 
with CAD and in the general population [28, 41]. In 
addition, plasma NGAL was strongly associated with 
total leucocyte and neutrophil count [41]. The same 
was true for the diabetic patients in our study. Addi-
tionally we demonstrated here the increased number of 
leukocytes in carotid plaques of diabetics in comparison 
to non-diabetics.
HbA1c significantly influenced NGAL, but not MMP-9/
NGAL levels in our cohort of patients, which comprised 
relatively well medically adjusted diabetics with a median 
 HbA1c level of 6.8%. Moreover, besides MMP-9, NGAL 
possesses various ligands such as siderophores contribut-
ing to the broad range of different functions [42]. The lat-
ter may explain why in case of NGAL elevation MMP-9/
NGAL complex has not to be necessarily elevated, too. 
The duration of T2DM had no effect on NGAL levels, 
illustrating that the current inflammatory state along 
with the current  HbA1c level is of more importance. 
These findings are in agreement with previous reports 
[38, 39].
Risk for cerebral embolization
CAS in type 2 diabetics is characterized by an increased 
risk for cerebral embolization. In the present study 
proven embolization was almost twice as high in patients 
with T2DM as compared to non-diabetics, which con-
firmed previous results [19, 43]. Interestingly, NGAL lev-
els were highest in diabetic patients with symptomatic 
CAS. Moreover, NGAL mRNA expression was found 
in atherosclerotic tissue of 95% of patients with T2DM 
compared to 5% in non-diabetics. Out of these patients, 
those with detectable mRNA expression for NGAL were 
more prone towards embolization. Although comparable 
data in patients with T2DM are missing, these findings 
are supported by Boeckhorst et  al., who reported that 
tissue NGAL expression was elevated in case of intra-
plaques hemorrhage or luminal thrombus [27]. In addi-
tion, carotid plaque NGAL was associated with high 
Fig. 3 NGAL and MMP‑9/NGAL serum levels are lower in metformin‑treated patients. Box‑whisker plot display serum NGAL (a) and MMP‑9/NGAL 
(b) concentrations stratified according to metformin treatment
Table 4 Univariate and  multiple linear regression models 
for serum NGAL (A) and MMP-9/NGAL (B, log-transformed) 
concentrations in diabetic patients
a Regression parameter (β) ± standard error (SE)
Univariate models Multiple model
β ± SEa p β ± SEa p
(A)
 Insulin −21.75 ± 14.41 0.136 −10.97 ± 13.30 0.413
 Metformin −74.67 ± 10.98 <0.0001 −74.60 ± 11.84 <0.0001
 Other anti‑DM 
medication
−7.56 ± 14.07 0.593 −7.31 ± 11.21 0.517
 HBA1c 5.81 ± 6.70 0.388 14.12 ± 5.94 0.021
 log_Neutrophils 33.68 ± 18.69 0.076 9.57 ± 14.88 0.523
(B)
 Insulin −0.29 ± 0.27 0.271 1.88 ± 1.02 0.072
 Metformin −0.69 ± 0.247 0.0067 −0.57 ± 0.28 0.043
 Other anti‑DM 
medication
0.0087 ± 0.258 0.973 0.04 ± 0.26 0.875
 HBA1c 0.05 ± 0.123 0.665 0.12 ± 0.14 0.405
 log_Neutrophils 0.821 ± 0.339 0.018 0.63 ± 0.35 0.073
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numbers of macrophages and high IL-6 and IL-8 levels 
[27]. These findings are in line with our previous inves-
tigation [23]. In addition, various studies demonstrated 
higher plaque MMP-9 levels in type 2 diabetics com-
pared to non-diabetics [16]. Moreover, plaque ulceration 
was reported to be significantly more common in carotid 
plaques of a cohort of 30 diabetics [19]. Likewise, type 
VI plaques were seen more frequently in patients with 
T2DM in our study. In addition, multiple linear regres-
sion analysis showed a significant influence of T2DM, 
symptomatic presentation of carotid stenosis and grade 
VI plaques on NGAL levels. In contrast, advanced grade 
of CAS did not alter plasma NGAL levels, as reported by 
Giaginis et al. [38]. Although it is far too early to describe 
serum NGAL as reliable biomarker for vulnerable CAS 
in patients with T2DM, enhanced NGAL concentrations 
in the circulation did not meet statistical significance for 
patients with a history of peripheral artery disease or 
CAD as described by Giaginis et al. previously [38].
Effect of metformin
Finally, we investigated the association of NGAL levels 
with metformin treatment that is generally prescribed as 
the first line treatment of T2DM. Next to glucose lower-
ing effect, metformin was recently discussed to have anti-
inflammatory and other pleiotropic effects [44, 45]. Xu 
et al. showed, that metformin lowered hs-CRP, IL-6, and 
TNF-α levels in diabetics and concluded that metformin 
has a protective potential to ameliorate the pro-inflam-
matory response in patients with CAS [44]. Moreover, 
metformin reduced endothelial cell production of IL-6 
in  vitro [46] and below-the-knee arterial calcification 
score in type 2 diabetics [47]. These patho-mechanisms 
may contribute to stabilization of carotid plaques in 
patients with T2DM and improve all-cause mortality and 
cardiovascular events [48]. An extremely low number of 
grade VI plaques in patients with T2DM and metformin 
intake in our study add to these considerations.
Strength of the study
The strength of our investigation is a detailed work-up of 
histological specimen according to the AHA classifica-
tion against the background of the clinical situation. In 
addition, NGAL mRNA analysis was performed to gain 
information about NGAL expression in the atheroscle-
rotic lesion directly. We analyzed for the first time the 
association of metformin and NGAL levels in diabetic 
patients with CAS.
Limitations of the study
On the other hand the present study has several limita-
tions. The study was not designed with three arms ana-
lyzing type 2 diabetics without metformin compared to 
those with metformin and non-diabetics in three groups 
of equal number of patients. However, post hoc analy-
sis of patients with T2DM revealed the profound anti-
inflammatory effect of metformin on pro-inflammatory 
protein NGAL. In addition, the number of patients 
included in the investigation was limited. As a conse-
quence, further studies are necessary to rule out the exact 
pathomechanisms of metformin on NGAL and MMP-9/
NGAL levels in a larger series of patients.
Conclusion
In summary, the present investigation showed that type 
2 diabetics with high-grade CAS undergoing carotid 
endarterectomy have increased levels of NGAL system-
ically as well as locally within the plaque as compared 
to non-diabetics. Even in asymptomatic patients NGAL 
was elevated in diabetics compared to non-diabetics. 
NGAL mRNA carotid plaque expression was abun-
dant in diabetics and rarely found in non-diabetics. 
Fig. 4 Infiltration of leukocytes in carotid artery lesions is reduced in diabetics under metformin treatment. Light microscopic pictures of human 
carotid atherosclerotic lesion from non‑diabetic patients (a), from diabetic patients without metformin intake (b) and from diabetic patients with 
metformin intake (c). Hematoxylin–eosin staining. Original magnification ×40. Scale bar 320 nm. Representative pictures are shown
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NGAL levels being significantly influenced by pres-
ence of T2DM,  HbA1c and vulnerable plaques may 
indicate dangerous lesions prone for embolization. 
These findings reflect the fact that proven emboliza-
tion was almost twice as frequent in type 2 diabetics, 
which highlights the need for aggressive therapy in 
these patients. Metformin was obviously able to reduce 
the increased inflammatory state by lowering NGAL 
serum levels as well as leukocytes infiltration in carotid 
plaques.
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